New Guidelines, Emerging Treatments, and Unexpected Patients: Understanding the Challenges of PAH 

Target Audience
This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH. 

Program Overview
It is a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple drug classes and combinations thereof that are used to target the molecular drivers of this disease. They will also need to be able to recognize PAH in patients they might never suspect of having this disease, namely children and adults exposed to illicit stimulant drugs.

Premiere clinical guidelines on diagnosing and managing PAH were recently updated and in March 2024, two new treatment choices were approved by the FDA " a first-in-class add-on treatment that can enhance therapeutic response and a fixed-dose, single-tablet combination of the two drug classes that the guidelines recommend as initial treatment for most patients. Join PAH expert Dr. John J. Ryan for this Nurse Practitioners’ Summit special course on recent guideline changes, newly approved treatments, and more.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

Discuss recently published recommendations for diagnosing and managing PAH
Summarize ways to identify and manage children with PAH and adults with methamphetamine-associated PAH 
Describe how to include new therapies into treatment and monitoring strategies based on efficacy and safety findings from clinical trials